Xiamen debuts Alzheimer's disease treatment

2024-07-10 14:43
A patient with the early stages of Alzheimer's disease received Xiamen's first dose of lecanemab at the First Affiliated Hospital of Xiamen University earlier this month. 
This marks the first prescription of anti-amyloid antibodies issued in Xiamen. Studies suggest that the treatment can delay the progression of Alzheimer's by approximately five months.


Lecanemab is the first approved drug in China to target amyloid plaques in the brain, which are believed to be one of the underlying causes of Alzheimer's disease. 


Potential patients must undergo a detailed screening process, including a PET scan or a lumbar puncture and an M.R.I., to check for other potential causes of brain disease.

[ Web editor:吴键涵,王付东    Source:Common Talk ]